Top EU Firms Cut Investment Less than US Rivals, but Europe Still Well Behind

The European Commission's 2010 "EU Industrial R&D Investment Scoreboard" shows that R&D investment by top EU companies fell by 2.6% in 2009, even though sales and profits fell much more, by 10.1% and 21.0% respectively. The fall in R&D investment by leading players in the US, at 5.1%, was twice as sharp as in the EU, but the worldwide reduction was lower, at 1.9%. Japanese firms maintained their level of investment. Companies based elsewhere in Asia - China, India, Hong Kong, South Korea and Taiwan - continued the high R&D growth seen in previous years. Japanese car maker Toyota is the world's biggest R&D investor (€6.8bn) for the second consecutive year. Three EU companies feature in the top ten: Volkswagen, the biggest investor based in Europe with €5.8bn, Nokia and Sanofi-Aventis. The Scoreboard covers the top 1400 companies worldwide.

Máire Geoghegan-Quinn, Commissioner for Research, Innovation and Science said: "The fact that major EU firms have largely maintained their R&D investment shows that they recognise R&D as key to emerging stronger from the crisis. But the wide gap with the top US companies in areas like software and biotechnology and the continuing rapid rise of Asian-based companies highlight the innovation emergency Europe is facing. We urgently need heads of state and government at the December European Council to back the Innovation Union proposals that Antonio Tajani and I announced on 6 October."

This year's Scoreboard shows that despite almost unprecedentedly difficult economic conditions R&D investment remains an important strategic priority for top firms worldwide.

Trends in world regions
During 2009, leading EU companies reduced R&D investments much less than their US counterparts despite similar drops in sales (around 10%) and higher drops in profits (13.0% as against 1.4%)

European companies' R&D performance is weak in key hi-tech sectors. For example the US companies featured in the Scoreboard invested five times more than their EU counterparts in R&D on semiconductors, four times more in software R&D and eight times more in biotechnology.

Japanese companies maintained R&D investment despite strong decreases in sales (around 10%) and profits (88.2%).

Major companies headquartered in some Asian countries continued the high R&D growth of previous years, e.g. China (up 40.0%), India (27.3%), Hong Kong (14.8%), South Korea (9.1%) and Taiwan (3.1%). Swiss companies also increased R&D investment (2.5%).

Company and sector trends
Three companies headquartered in the EU are among the top ten R&D investors (Volkswagen, Nokia and Sanofi-Aventis), along with three from the US (Microsoft, Pfizer and Johnson & Johnson), and one from Japan (Toyota, in top position). The top 50 includes 16 EU companies, 19 US firms and 12 from Japan (fig. 2). 30 of the top 50 cut R&D investment in 2009.

Despite the crisis, the sectoral composition of R&D investment worldwide has remained broadly the same. For US companies, high R&D-intensity sectors, such as pharmaceutical or computer services, contribute to more than two-thirds of the total R&D. By contrast, for European and Japanese companies, medium-high R&D intensity sectors (for example automobiles or electronics) predominate, while the high R&D intensity sectors constitutes only around one-third of the total investment.

There were massive reductions in R&D investment by some automotive firms, e.g. Ford (32.4%), Renault (26.5%) and General Motors (24.1%). Others such as Nissan and Toyota showed a modest reduction or even increased R&D investment, e.g. Hyundai.

Companies boosting R&D investment in 2009 included not only those with good sales and profits such as Huawei Technologies (27.8%) and Apple (25.4%), but also some firms, such as Bayer (8.8%) and General Electric (10.1%), that increased R&D while profits and sales fell.

The alternative energy sector continued to grow rapidly. The Scoreboard now includes 15 companies (9 more than last year) fully focused on clean energy technology. These companies, 13 based in the EU and 2 elsewhere, invested more than €500 million in R&D in 2009, an increase of 28.7%. Alternative energy investments are also made by companies classified under other sectors, e.g. oil & gas.

Differences across EU - Spain's top R&D investors resist the crisis
Within the EU, R&D growth rates differ between Member States due to their varied sector composition. Some of the biggest R&D decreases in 2009 were by companies based in countries such as Germany (down 3.2%) and France (4.5%) with a large automotive industry.

Countries like Finland (down 6%) and Sweden (6.6%) where IT hardware is a major industry for home-based companies were also hit hard.

However, Spain's top R&D investors increased investment by 15.4%, despite a drop in sales of 6.4%. This was due to large increases by top Spanish companies such as Telefónica (16%) and Acciona (29%) and the inclusion of top players such as Banco Santander (18%).

The EU Industrial R&D Investment Scoreboard is published annually by the European Commission (DG Research and Joint Research Centre) and provides information on the world's top 1400 companies (400 from the EU and 1000 from outside) ranked by their investments in R&D. It measures the total value of their global R&D investment, irrespective of the location where the relevant R&D takes place. It does not therefore indicate trends in private sector R&D intensity – business R&D expenditure in a particular country or region as a proportion of GDP, whether that expenditure is by home-grown companies or through inward investment.

Download
2010 "EU Industrial R&D Investment Scoreboard" and other IRMA (Industrial Research Investment Monitoring and Analysis) reports: http://iri.jrc.ec.europa.eu/reports.htm

Most Popular Now

Research Shows AI Technology Improves Pa…

Existing research indicates that the accuracy of a Parkinson's disease diagnosis hovers between 55% and 78% in the first five years of assessment. That's partly because Parkinson's sibling movement disorders...

Who's to Blame When AI Makes a Medi…

Assistive artificial intelligence technologies hold significant promise for transforming health care by aiding physicians in diagnosing, managing, and treating patients. However, the current trend of assistive AI implementation could actually...

First Therapy Chatbot Trial Shows AI can…

Dartmouth researchers conducted the first clinical trial of a therapy chatbot powered by generative AI and found that the software resulted in significant improvements in participants' symptoms, according to results...

DMEA sparks: The Future of Digital Healt…

8 - 10 April 2025, Berlin, Germany. Digitalization is considered one of the key strategies for addressing the shortage of skilled workers - but the digital health sector also needs qualified...

DeepSeek: The "Watson" to Doct…

DeepSeek is an artificial intelligence (AI) platform built on deep learning and natural language processing (NLP) technologies. Its core products include the DeepSeek-R1 and DeepSeek-V3 models. Leveraging an efficient Mixture...

Stepping Hill Hospital Announced as SPAR…

Stepping Hill Hospital, part of Stockport NHS Foundation Trust, has replaced its bedside units with state-of-the art devices running a full range of information, engagement, communications and productivity apps, to...

DMEA 2025: Digital Health Worldwide in B…

8 - 10 April 2025, Berlin, Germany. From the AI Act, to the potential of the European Health Data Space, to the power of patient data in Scandinavia - DMEA 2025...